MedTrace Logo

Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)

NCT03828942 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-04-13

No results posted yet for this study

Summary

Several drugs and chemotherapies seem to have an impact on the hematological system. This study investigates reports of hematological toxicities, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Conditions

  • Hematological Abnormality
  • Hematotoxicity

Interventions

DRUG

drug inducing hematological toxicity

Drugs susceptible to induce hematological toxicities

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2022-02-01
Completion
2023-04-08
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03828942 on ClinicalTrials.gov